POS0122 INVESTIGATION OF SERUM MARKER LEVELS IN CONNECTIVE TISSUE DISEASES DEVELOPING ILD

Background Connective tissue disease (CTD) is an umbrella term for a heterogeneous group of autoimmune diseases affecting the connective in various organs. One most serious complications associated with CTDs interstitial lung (ILD), which results significant morbidity and mortality. A subset CTD-ILD patients shows progressive disease, even worse prognosis. Previous studies have identified dysregulations biomarkers including CX3CL1, CCL2, CCL17 CCL18 systemic sclerosis (SSc) showing association ILD [1-4]. For other it less clear, are progression few assessed circulating across CTD-ILDs. Objectives To investigate patients. Methods Serum samples from SSc (n=292), primary sjogrens syndrome (pSS) (n=132), mixed (MCTD) (n=162), anti-syntetase (ASS) (n=72) healthy controls (HC) (n=100) collected at Oslo University Hospital (OUH) were analyzed by ELISA selected (CX3CL1, CCL17, CCL18). used as reference to compare mean levels serum markers pSS, ASS MCTD. was diagnosed on high resolution computed tomography (HRCT). Forced vital capacity (FVC) available baseline 12 +/- 3 months. defined absolute FVC% predicted decline ≥10% assessed. Descriptive statistics logistic regression odds ratio (OR) 95%CI performed. Results CX3CL1 significantly higher all (p<0.001) compared HC. CCL2 (p=0.001 p<0.001), (p<0.001 p=0.004) MCTD p<0.001) HC, but not pSS (p=0.230 p=0.087). Of CTD patients, 267/658 (41%) (table 1). these 80 (30%) showed progression, where data obtained SSc, (Tabel All no while only inn ASS-ILD none MCTD-ILD. When using SSc-ILD pSS-ILD MCTD-ILD (p<0.001), lower (p<0.001). did differ between CTD-ILDs (Figure 1A). From analysis patient (OR: 1.19, 95%CI, p=0.001) marker progression. adjusting also here 1.06, 95%CI: 1.03-1.09, 1B). Conclusion In this large cohort, we show that increased ILD, could help us identify ILD. CCL18, driven subpopulation. Table 1. Clinical demographic (n=292) (n=132) (n=162) Females, (%) 239 (61) 123 (93) 48 (67) 128 (79) Age onset, yrs (SD) (15.4) 52 (14.1) 49 (12.8) 35 (15.7) FVC baseline, % 95 (20.3) 99 (12.7) 85 (21.8) 92 (18.5) 140 (47.9) 16 (12.1) 60 (83.3) 51 (31.5) n 74 (26) (19) (6) - Mean ng/ml 49.3 (10.8) 47.4 (12.5) 50.5 (11.2) 43.8 (9.8) 0.6 (0.7) 0.5 (0.2) 0.9 (0.5) 0.7 (0.8) (0.6) 1.9 (2.5) 3.2 (6.3) 2.0 (2.9) 3.4 (5.6) Figure (A) SSc-ILD, pSS-ILD, MCTD-ILD, (B) reference. REFERENCES: NIL. Acknowledgements: Disclosure Interests Henriette Didriksen: None declared, Håvard Fretheim Speakers bureau: Boehringer Ingelheim, Consultant of: Bayer, Grant/research support from: GSK/Actelion, Helena Andersson: Silje Reiseter: Ragnar Gunnarsson: Emily Langballe: Torhild Garen: Øyvind Midtvedt: Thor Ueland: Molberg: Anna-Maria Hoffmann-Vold Janssen, Medscape, Merck, Sharp & Dohme Roche, ARXX, Genentech, Genentech Janssen.